NCT05010954已完成3 期
A Multi-center, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Compared to Lansoprazole in the Treatment of Duodenal Ulcer in Chinese Patients for up to 6 Weeks
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2021年10月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Cumulative endoscopic healing rate
研究概览
简要总结
This is a multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50mg comparing with Lansoprazole 30 mg after the treatment of duodenal ulcer in Chinese patients for up to 6 weeks.
详细描述
Screening-eligible subjects will be randomized into LXI-15028 50 mg group or Lansoprazole 30 mg group at Visit 1 at the ratio of 1:1 and receive study treatment continuously for 4 or 6 weeks.Subjects will take the first dose of the investigational drug on the morning of the randomization day or on the next morning of the randomization day, and start to complete the subject's diary from the day of study treatment initiation(Day 1). After 4 weeks treatment, subjects will return to the study institution for Visit 3. For the subjects who achieve endoscopic healing at Visit 3,the study treatment will be terminated.The subjects who fail to achieve endoscopic healing at Visit 3 will receive newly dispensed investigational products for another 2 weeks' treatment and then complete Visit 4.All subjects will receive telephone follow-up (Visit 5) on Day 28 ± 3 after the last dose of the investigational products.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject who volunteers to sign the written informed consent form approved by the Ethics Committee and agrees to participate in this study prior to the initiation of any study procedures.
- •Subject who is able to understand and follow the protocol requirements and agrees to participate in all the study visits.
- •Male or female subjects with age ≥18 years and ≤70 years.
- •Subject who is diagnosed as active DU (at least one ulcer, but not more than two ulcers, with the bigger one 0.3-2.0 cm in diameter) by upper gastrointestinal tract endoscopy in the same study institution within 14 days prior to the first dose of investigational drug and is staged as A1 or A2 by using the staging system of Sakita-Miwa.
- •Subject who agrees to use appropriate medical method for contraception during the course of the study (not including women in medically sterile state)
排除标准
- •Subject who had participated in any other clinical study of LXI-15028 previously, or had been treated with any P-CAB drug before.
- •Participation in other clinical study within 4 weeks prior to the first dose of study drug, except for the two following circumstances:
- •The study which the subject is participating or participated in is a non-interventional study (e.g. observational study or questionnaire survey) and is judged by investigators to have no interference with the efficacy and safety evaluation in the present study;
- •Subject had signed the informed consent form in that study, but withdrew from that study prior to the start of any treatment.
- •Subject who participates in the planning or conduct of this study.
- •Pregnant or lactating women.
- •Subject who is known to be allergic to the active ingredient or excipient of the investigational drug (including Lansoprazole).
- •Subject who is unable to undertake an upper gastrointestinal tract endoscopy.
- •Subject who is unable to complete the subject diary by his/her own.
- •Subject who has history of manic-depression, somatoform disorder, personality disorder, schizophrenia or other severe mental disorder.
- •Ulcers caused by endoscopic procedures, e.g. post endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) ulcers.
- •Zollinger-Ellison syndrome.
- •History of malignant tumor within 5 years prior to screening (if the subject's basal cell carcinoma or cervical carcinoma in situ has been cured, he/she will be allowed to participate in this study).
- •Subject with history of upper GI surgery (except endoscopic surgery such as resection of benign polyp, etc.).
- •Subject who plans to be hospitalized for receiving selective surgery during the study.
- •Subject with uncontrolled and unstable hepatic, renal, cardiovascular, respiratory, endocrine, hematologic or central nervous system disease as judged by investigators.
- •Subject with history of chronic alcohol consumption [more than 14 units per week, each unit corresponds to 360 mL beer (ABV ≈ 5%) or 45 mL spirit (ABV ≈ 40%) or 150 mL wine (ABV ≈ 12%)] or drug abuse within 5 years prior to screening.
- •Subject whose upper gastrointestinal tract endoscopy shows GI bleeding (grade I, IIa or IIb per Forrest classification), esophageal stenosis, ulcerative stenosis, pyloric stenosis, gastroesophageal varices, Barrett's esophagus >3 cm (i.e., long-segment Barrett's esophagus, LSBE), gastroesophageal reflux disease, acute gastroduodenal mucosal lesion (AGDML), active gastric ulcer, refractory ulcer, ulcer perforation or suspected malignant disease.
- •Subject who has other severe GI diseases such as Crohn's disease, ulcerative colitis, etc.
- •Use of any PPI, anticholinergic drug, gastrin receptor antagonist, H2 receptor antagonist, prostaglandin, mucosal protective agent, prokinetic, antacid or any other therapeutic drugs for peptic ulcer within 14 days prior to the first dose of study drug.
- •Subject who has thrombotic disease (e.g., cerebral thrombosis, myocardial infarction, thrombophlebitis, etc.) or is currently on anticoagulant therapy.
- •Subject who needs to use nonsteroidal anti-inflammatory drugs (NSAIDs) continuously during the course of the study.
- •Use of any antipsychotic, antidepressant or anti-anxiety agent during screening.
- •Any of the following laboratory abnormalities at screening:
- •AST > Upper limit of normal (ULN);
- •ALT > ULN;
- •Total bilirubin > ULN;
- •Creatinine > 1.5 × ULN;
- •Platelet<lower limit of normal
- •Prothrombin time>1.5 × ULN
- •Subject who has clinically significant abnormality in electrocardiogram (ECG), including severe arrhythmia, multifocal premature ventricular contraction (PVC), Ⅱ or above atrioventricular block, etc.
- •Human immunodeficiency virus (HIV) antibody (+), hepatitis B virus (HBV) surface antigen (+) or hepatitis C virus (HCV) antibody (+) confirmed by tests.
- •Judged by the investigator, there are other conditions compromising the subject's eligibility for this study.
研究组 & 干预措施
LXI-15028 50mg group(n=200)
Experimental
干预措施: LXI-15028 50mg group (Drug)
Lansoprazole 30mg group (n=200)
Active Comparator
干预措施: Lansoprazole 30mg group (Drug)
结局指标
主要结局
Cumulative endoscopic healing rate
时间窗: 4 or 6 weeks after receiving oral doses
次要结局
- Endoscopic healing rate at Week 4(4 week after receiving oral doses)
- Symptom assessment based on subject diary(4 or 6 weeks after receiving oral doses)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of AsthmaAsthmaNCT01687296GlaxoSmithKline261
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-203Acute GastritisChronic GastritisNCT04066530Addpharma Inc.475
已完成
4 期
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.Acute GastritisChronic GastritisNCT01817556Dong-A ST Co., Ltd.258
进行中（未招募）
3 期
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsParkinson's DiseaseNCT04006210NeuroDerm Ltd.381
已完成
3 期
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)HypercholesterolemiaNCT00650819Organon and Co240